Showing 3761-3770 of 5621 results for "".
- Lensar and Oertli Provide Update on Plans to Integrate Phaco Technology into the ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/lensar-and-oertli-provide-update-on-plans-to-integrate-phaco-technology-into-the-ally-adaptive-cataract-treatment-system/2481923/Lensar said it is closer to its plans to integrate phacoemulsification technology from Oertli Instrumente into the ALLY Adaptive Cataract Treatment System. Oertli filed with the FDA a 510(k) for their Faros device, which if cleared, will bring Lensar a step closer to deliver comb
- FDA Warns Consumers Not to Purchase or Use 27 Brands of Eye Dropshttps://modernod.com/news/fda-warns-consumers-not-to-purchase-or-use-26-brands-of-eye-drops/2481919/In its most wide-reaching warning yet, the FDA advised consumers not to purchase and to immediately stop using 27 ov
- FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)https://modernod.com/news/fda-approves-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo/2481917/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The approval for RVO marks the third indication for Vabysmo, along with wet age-related macular degeneration (AMD) and diabetic macular edem
- Vision Innovation Partners Names Chris Moore as CEOhttps://modernod.com/news/vision-innovation-partners-names-chris-moore-as-ceo/2481914/Vision Innovation Partners (VIP), a Mid-Atlantic eye care platform with nearly 70 locations, announced the promotion of existing board member and current President, Chris Moore, to Chief Executive Officer. Former CEO and founder Mike Dunn is now serving as Executive Vice President of Business Dev
- Bausch + Lomb Introduces New Surgical Planning Software for Eyetelligence Platformhttps://modernod.com/news/bausch-lomb-introduces-new-surgical-planning-software-for-eyetelligence-platform/2481907/Bausch + Lomb introduced new surgical planning software for the Eyetelligence platform designed to streamline surgical planning, information flow, and enable elect
- Lighthouse Guild Presents 2023 Awardshttps://modernod.com/news/lighthouse-guild-presents-2023-awards/2481905/Lighthouse Guild hosted its 2023 lecture and awards ceremony at its headquarters in New York on October 19. The awards recognize outstanding accomplishments in vision science, technological innovation, and advocacy. Wiley A. Chambers, MD, was awarded
- Stuart Therapeutics Enters License Agreement with Glaukos for Preclinical Glaucoma Drug Candidatehttps://modernod.com/news/stuart-therapeutics-enters-license-agreement-with-glaukos-for-preclinical-glaucoma-drug-candidate/2481904/Stuart Therapeutics has entered into a license agreement with Glaukos under which it has granted Glaukos exclusive worldwide rights to develop and commercialize Stuart's proprietary ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a pat
- The Lancet Publishes 24-Month Results from Phase 3 Studies of Syfovre for GAhttps://modernod.com/news/the-lancet-publishes-24-month-results-from-phase-3-studies-of-syfovre-for-geographic-atrophy/2481901/Apellis Pharmaceuticals announced that The Lancet has published 24-month results from the phase 3 OAKS and DERBY studies evaluating Syfovre (pegcetacoplan injection)
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLshttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols/2481897/Bausch + Lomb announced the launch of the enVista Aspire monofocal and toric IOLs in the United States. The enVista Aspire IOLs featured B+L's Intermediate Optimized (IO) optics, which are designed for a broader depth of focus, with the benefits of the enVista platform to address patient
- FDA Finds 'Substantive' Issues in Aldeyra’s NDA for Reproxalap for Dry Eye Diseasehttps://modernod.com/news/fda-finds-substantive-issues-in-aldeyras-reproxalap-drug-candidate-for-dry-eye-disease/2481895/Aldeyra Therapeutics was dealt a major setback this week as the FDA identified "substantive review issues" in the company’s new drug application for dry-eye disease treatment candidate reproxalap. In a US securities